This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …

Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …

Summary Background The PROUD-PV and CONTINUATION-PV trials aimed to compare the
novel monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard …

Overview: Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent
myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often …

Philadelphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 …

Background There is no evidence that phlebotomy alone is sufficient to steadily maintain
haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to …

Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera
(PV) but can diminish the mutant JAK2V617F allele burden [1, 2, 3]. After discontinuing long …

Background In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK) 1 and JAK2
inhibitor, was superior to best available therapy at controlling haematocrit and improving …

Prior studies have reported high response rates with recombinant interferon-α (rIFN-α)
therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To …

Disease overview Polycythemia vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and …